Among 58 clinically diagnosed patients within the FTD spectrum, we identified pathogenic mutations in three individuals (5.2%), comprising two MAPT carriers and one C9orf72 expansion carrier, while no GRN mutations were detected. This evidence concerns the gene MAPT and frontotemporal dementia.